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Abstract
Background—Knowledge of factors associated with the course of lower urinary tract symptoms 
(LUTS) before treatment is needed to inform preventive interventions. In a prospective study of 
elderly men untreated for LUTS, we identified factors associated with symptom progression and 
remission.
Methods—In community dwelling U.S. men age ≥ 65 years, the American Urological 
Association Symptom Index (AUA-SI) was repeated four times, once at baseline (2000–2002) and 
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then every two years thereafter. Analyses included 1740 men with all four AUA-SI assessments, 
who remained free from diagnosed prostate cancer, and who reported no treatment for LUTS or 
benign prostatic hyperplasia (BPH) during follow-up that averaged 6.9 (±0.4) years. LUTS change 
was determined with group-based trajectory modeling of the repeated AUA-SI measures. 
Multivariable logistic regression was then used to determine the baseline factors associated with 
progressing compared to stable trajectories, and with remitting compared to progressing 
trajectories. Lifestyle, body mass index (BMI) (kg/m2), mobility, mental health (Short-Form 12), 
medical history, and prescription medications were considered for selection. Odds ratios (OR) and 
95% confidence intervals (CI) were estimated for variables in each model.
Results—We identified 10 AUA-SI trajectories: four stable (1 277 men, 73%), three progressing 
(345 men, 20%), two remitting (98 men, 6%), and one mixed (20 men, 1%). Men in progressing 
compared to stable trajectories were more likely to have mobility limitations (OR=2.0, 95% CI: 
1.0–3.8), poor mental health (OR=1.9, 95% CI: 1.1–3.4), BMI ≥ 25.0 kg/m2 (OR=1.7, 95% CI: 
1.0–2.8), hypertension (OR=1.5, 95% CI: 1.0–2.4), and back pain (OR=1.5, 95% CI: 1.0–2.4). 
Men in remitting compared to progressing trajectories more often used central nervous system 
medications (OR=2.3, 95% CI: 1.1–4.9) and less often had a history of problem drinking (OR=0.4. 
95% CI: 0.2–0.9).
Conclusions—Several non-urological lifestyle and health factors were independently associated 
with risk of LUTS progression in older men.
Keywords
cohort studies; elderly; lower urinary tract symptoms; male; risk factor; trajectory
Introduction
Male lower urinary tract symptoms (LUTS) represent a cluster of chronic urinary disorders 
that are highly prevalent worldwide,1,2 especially among elderly men.3,4 Multiple etiologies 
including benign prostatic hyperplasia (BPH) and bladder overactivity manifest as LUTS.5 
LUTS severity is assessed with the validated American Urologic Association Symptom 
Index (AUA-SI) or International Prostate Symptom Score (IPSS).6 Moderate and severe 
LUTS exert a substantial negative effect on public health through diminished quality of 
life,7,8 increased risk of falls and mortality,9,10 and annual treatment costs totaling upwards 
of $3.9 billion in the US.11,12 Given that the average life expectancy among US men who 
reach age 65 years has increased in the past decade,13 the health burden of male LUTS is 
unlikely to abate without preventive interventions.
Prevention of LUTS progression requires knowledge of the natural symptom course before 
treatment is initiated. To date, prospective studies of risk factors for LUTS included a 
mixture of men with and without treatment.14–17 However, factors other than symptom 
severity influence treatment decisions18 and men with mild symptoms often report 
treatment.8,19 Therefore, to distinguish risk factors for natural LUTS progression, additional 
studies among untreated men are needed.
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Symptom progression is just one aspect of LUTS natural history in men.20–26 Apparently 
spontaneous symptom remission and symptom stability are also consistently 
documented.20–26 Identification of these patterns requires repeated AUA-SI or IPSS 
assessments, because LUTS fluctuate considerably within men over time.20 To date, nearly 
all previous studies of LUTS risk factors assessed symptom change between only two time 
points. Additionally, a single study has reported factors associated with LUTS remission.17 
Identifying risk factors separately for LUTS progression and for LUTS remission may 
reveal novel pathways of LUTS etiology, which could enhance the translational potential for 
prevention and control of this condition.
This study had two objectives. First, to characterize the natural course of untreated LUTS 
beyond two time points, we applied group based trajectory models27,28 to four repeated 
assessments of the AUA-SI in a large cohort of elderly men. Trajectory analysis is a 
statistical technique designed to identify mutually exclusive groups of subjects who follow a 
similar longitudinal pattern while accounting for individual heterogeneity in repeated 
measurements of an outcome variable. This method is gaining recognition in medical 
research,29 but it has yet to be applied to LUTS. Second, to elucidate potential targets for 
LUTS prevention, we determined the independent associations of progressing and remitting 
LUTS trajectories with a comprehensive set of baseline lifestyle and health factors.
Subjects and Methods
Setting
We used data collected prospectively in the Osteoporotic Fractures in Men (MrOS) Study, a 
cohort of community-dwelling men aged ≥ 65 years. Participants were recruited in 2000–
2002 from six US regions.30,31 Men completed baseline questionnaires and in-person 
research visits. Subsequently, data were updated about every two years (Figure 1). 
Institutional Review Boards at each institution approved the study. All men gave written 
informed consent.
Urinary measures
The AUA-SI, prostate disease history, and medication use were obtained at all four time 
points. Categories of LUTS severity defined from the AUA-SI were mild (0–7 points), 
moderate (8–19 points) or severe (20–35 points).6 Urinary bother was categorized as 0–2, 3, 
and 4–6.6 Men reported histories of diagnosed BPH, laser surgery or transurethral resection 
of the prostate, and medication use for prostate symptoms. Current prescription medications 
were inventoried at each time point and matched to ingredients using a standardized 
method32 as described previously.16,25 LUTS medications were alpha-blockers, urinary 
antispasmodics, anticholinergics, and 5-alpha-reductase inhibitors.
Baseline factors
Cigarette smoking was coded into lifetime pack-years and current alcohol consumption into 
average drinks per week. History of problem drinking was defined as 2–4 positive responses 
to the CAGE questionnaire.33,34 Caffeine consumption (mg/day) was obtained from a Block 
Food Frequency Questionnaire35 and categorized into quartiles. Physical activity was 
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obtained with the validated Physical Activity Scale for the Elderly (PASE), which assesses 
amount of leisure and household activities.36 Self-reported daily walking for exercise was 
also assessed. Mobility limitation was defined as difficulty walking two to three blocks or 
difficulty climbing one flight of stairs.37 Health related quality of life was obtained with the 
Short Form-12 (SF-12) Physical Component (PCS) and Mental Component (MCS) scores.38 
MCS ≤ 50 is a valid measure of common mental health disorders (depression or anxiety 
disorders).39 Medical conditions included reports of physician-diagnosed diabetes, 
hypertension, angina, myocardial infarction, stroke, prostatitis, and cancers of the prostate, 
colon/rectum, lung and skin, as well as dizziness, history of falls and back pain in the past 
year.
Height and weight were classified into standard body mass index (BMI) (kg/m2) categories 
as <25.0 (normal), 25.0–29.9 (overweight), or ≥ 30.0 (obese). 40 Baseline prescription 
medications included hypoglycemics (insulin, glucose), diuretics (thiazide, loop, and 
potassium sparing) and other anti-hypertensive (ACE inhibitors, angiotensin II receptor 
antagonists, beta blockers, calcium channel blockers), statins (HMG-CoA reductase 
inhibitors), and central nervous system (CNS) medications (antiepileptics, benzodiazapenes, 
antidepressants, opioids, sedatives). Alpha-blockers could not be included as anti-
hypertensives because use of these medications was an exclusion criterion (described 
below). Herbal supplements for LUTS were saw palmetto, South African star grass, stinging 
nettle, rye grass pollen, pumpkin seed, or African plum from self-report or inventory listing. 
Men with missing medication information were coded as non-users, because results with this 
coding were similar to results excluding the missing observations.
Analytic cohort
The 3 594 men with no baseline history of prostate cancer, BPH surgery, or medication use 
for LUTS or BPH were followed through the fourth AUA-SI assessment. Men who died or 
withdrew (n=456, 12%), had incident prostate cancer (n=213, 6%), missing AUA-SI 
(n=120, 3%), reported BPH treatment or used prescription LUTS medications (n=946, 
26%), were excluded (Figure 1). The analytic cohort of 1 740 had mean (sd) follow-up of 
6.9 (0.4) years. Treatment onset, which may occur in men with mild LUTS,19 was not used 
as a marker of LUTS progression.
Statistical analyses were performed with SAS 9.1 software (SAS Institute, Cary NC). Two-
sided p-values were estimated.
LUTS trajectory analysis
Group-based trajectory modeling was applied to the repeated AUA-SI scores as the 
continuous dependent variable. Trajectory modeling applies a semi-parametric mixture 
model to longitudinal data using the maximum likelihood method.27 This method assumes 
that the population contains an unspecified number of underlying groups, each with different 
probability distribution for the longitudinal sequence of the dependent variable. Modeling 
started with three trajectories. As the trajectory number was successively increased by one, 
model fit was assessed with the product two times the change in the Bayesian Information 
Criterion (2ΔBIC). Values >10 are considered evidence of better fit of the larger trajectory 
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number compared to the next smallest.27,28 Mean posterior probabilities in each trajectory 
were computed and values >0.70 indicate high internal reliability.27 We specified that the 
sample size in any trajectory must be at least 1% of the analytic cohort. Ultimately, the 10 
trajectory model optimized fit, internal reliability, and sample size. Plots of individual AUA-
SI scores in each trajectory confirmed that trajectory analysis successfully grouped men with 
similar longitudinal patterns (see examples in the online supplemental Figure).
Risk factor analyses
We performed risk factor analyses within strata of mild or moderate baseline LUTS. Too 
few men had severe untreated baseline LUTS for further study. In each stratum, men with 
stable trajectories formed the referent group to whom men with progressing LUT were 
compared. Men with remitting LUTS were compared men with progressing LUTS, because 
factors associated with symptom improvement could also inform LUTS prevention. Baseline 
variables that differed between the outcome and referent groups with p-values ≤ 0.25 were 
candidates for selection in forward, stepwise logistic regression modeling.
In separate models for each comparison defined above, candidate variables associated with 
the outcome at p ≤ 0.15 were retained. We used this larger alpha-level so as not to ignore 
potentially important associations for variables with low baseline prevalence. When a 
medical history variable was replaced with an appropriate medication variable, model fit 
worsened. Therefore, final models contained the medical history variables. BMI categorized 
as ‘normal’ and ‘overweight/obese’ improved model fit. Odds ratios (OR) and their 95% 
confidence intervals (CI) are reported for the final multivariable models.
Results
The 1 740 men in the analytic cohort reflected the baseline untreated cohort on nearly all 
characteristics including mean age, but had slightly lower mean AUA-SI scores (Table 1). In 
the analytic cohort, mean (sd) change in the AUA-SI score from baseline to the fourth 
assessment was 1.0 (4.6).
Trajectory results
We identified 10 trajectories of AUA-SI scores (Figure 2), illustrated with mean scores at 
each time point. Four trajectories consistent with LUTS stability (blue) contained 1 277 
(73%) men and were observed in the low and high AUA-SI range. Three trajectories 
consistent with progression (red) contained 345 men (20%), were primarily in the moderate 
range, and had distinct profiles including abrupt increase late in follow-up. Two trajectories 
consistent with remission (green) contained 98 (6%) men and were in the moderate-high 
range. One trajectory had mixed progression and remission (yellow) and contained 20 men 
(1%).
Supplemental tables S1–S3 provide mean posterior probabilities and distributions of urinary 
measures in each trajectory. Patterns of urinary bother, which increased in progressing 
groups and decreased in remitting groups, further support the internal consistency of the 
trajectory results.
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Percentages of men in stable, progressing or remitting trajectories differed by baseline 
LUTS severity (Figure 3). In men with mild baseline LUTS, 90% were in stable trajectories. 
Of men with moderate baseline LUTS, 49% were classified into progressing and 17% into 
remitting trajectories. Of the 28 men had severe baseline LUTS, most were classified into 
remitting or stable trajectories.
Risk factors
In univariable analyses, men in progressing compared to stable trajectories more often had 
MCS <50, history of hypertension, and back pain, regardless of baseline LUTS category 
(Table 2). Within strata, several additional factors differed between men in progressing 
compared to stable trajectories. Among men with moderate baseline LUTS, those in 
remitting compared to progressing trajectories (Table 3) less often had high BMI, ≥ 40 pack-
years of smoking, problem drinking, high caffeine intake, diabetes, hypertension, angina, or 
anti-hypertensive medication use (especially diuretics), but more often used CNS 
medications.
In multivariable analyses among men with mild baseline LUTS (Table 4), men with MCS 
<50, history of non-prostate cancer, mobility limitations, overweight, dizziness, and no daily 
walking for exercise were 1.5- to 2-fold more likely to have progressing compared to stable 
LUTS. When PASE score replaced the walking variable, the OR was elevated for the lowest 
level of physical activity (0–99 points) compared to the highest (≥200 points) (1.6, 95% CI:
0.9–2.9) but were null for 100–149 (0.8, 95% CI: 0.5–1.5) and 150–199 points (0.9, 95% CI: 
0.5–1.5).
Among men with moderate baseline LUTS, those with progressing compared to stable 
LUTS were 1.5–2.5-fold more likely to have MCS <50, hypertension, and back pain, and 
were less likely to have diabetes. Men with remitting compared to progressing LUTS were 
2.3-fold more likely to use CNS medications at baseline, but were less likely to have 
histories of problem drinking, hypertension, or angina.
Discussion
Several distinct AUA-SI trajectories were identified among 1740 elderly men untreated for 
LUTS and trajectory types differed by baseline LUTS severity. Most men with mild baseline 
LUTS followed stable trajectories, whereas half of men with moderate baseline LUTS 
experienced progression and a fifth experienced remission. These data may allow clinicians 
to advise older men that prospects for worsening (or improving) symptoms are based on 
their current symptom level. Similarly, the baseline lifestyle and health factors associated 
with LUTS progression differed somewhat for progression from mild or from moderate 
baseline symptoms. Clinical or public health interventions that target these factors within 
different levels of LUTS severity may promote the prevention of symptom progression in 
older men.
In our study, poor mental health was a strong risk factor for LUTS progression. LUTS 
remission relative to progression also was associated with factors that could influence 
mental well-being, such as use of CNS medications and problem drinking.41 In other 
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studies, depressive symptoms were associated with LUTS progression,17 but anti-depressant 
use was associated with higher likelihood of transition from mild to moderate LUTS.15 
Pharmacological modulation of CNS neurotransmitters, such as serotonin and GABA, may 
inhibit bladder overactivity and/or improve bladder capacity.42 It is therefore notable that 
use of benzodiazepines, which enhance GABA actions, was more common among men in 
remitting than in progressing trajectories in our study. Although use of certain CNS 
medications could worsen LUTS,15 their therapeutic potential warrants a more complete 
understanding of neurological contributions to lower urinary tract function.
The current results agree with our earlier report that LUTS progression is positively 
associated with overweight and inversely associated with physical activity.16 However, 
others showed no associations of BMI with LUTS progression14,15 or of physical activity 
with either LUTS progression or remission.17 In older men, overweight and low physical 
activity may contribute to lower urinary tract dysfunction through pathways involving 
microvascular disease,43,44 metabolic derangements,45 or autonomic nervous system 
overactivity.46 Consistent with these mechanisms, our results also show associations of 
hypertension and dizziness (a marker of orthostatic control) with LUTS progression. Our 
results also document that mobility and back pain may contribute to LUTS progression. Men 
with mobility limitations or back pain may perceive their symptoms as becoming more 
severe over time, if difficulty with ambulation alone, or because of pain, interferes with their 
ability get to or use a toilet. Alternatively, degenerative spinal conditions such as disc 
herniation or lumbar stenosis could contribute to both back pain and urologic dysfunction by 
impinging on the spinal cord or nerve roots.47–49
Risk factors for LUTS progression and remission identified in this study differ from those 
reported previously for three key reasons. First, we used trajectory modeling to account for 
LUTS fluctuation within men. Most earlier studies focused on change of a certain magnitude 
from a single previous time point, such as transition from mild (AUA-SI 0–7 points) to 
moderate LUTS (AUA-SI ≥ 8 points)15,16 or 2–3 point difference in AUA-SI voiding or 
storage subscores.17 These definitions may introduce misclassification if men who progress 
are combined with men whose symptoms are randomly fluctuating, or if men with stable and 
remitting symptoms are combined in the referent group. Misclassification would tend to bias 
associations with risk factors toward the null, which may explain why we but not 
others14,15,17 observed associations with BMI and physical activity. Second, we studied men 
with untreated LUTS. Studies that included a mix of men with and without treatment for 
LUTS may have identified factors associated with treatment decisions or treatment 
effects.14–17 Third, we studied older men whose risk factors for LUTS progression or 
remission may differ from those in younger men.
There are limitations to this research. First, we could not assess the reasons that men did not 
undergo treatment for LUTS. However, about 88% of men remained untreated at each 
AUA-SI assessment period, a proportion similar to that observed in other community-
dwelling cohorts,8,26 suggesting that the MrOS cohort is not unusual with regard to LUTS 
treatment initiation. Second, we did not have specific urological metrics. However, such 
measures would not have necessarily informed this analysis because our aim was to study 
long-term changes in urinary symptoms which are well-represented by the AUA-SI. Third, 
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some of the factors studied such as CNS medication use had low baseline prevalence, which 
resulted in wide confidence intervals for OR estimates. Finally, the analytic cohort consisted 
of men ages 65 or older who survived an average of 6.9 years and results may not apply to 
all men at risk for LUTS progression.
This study has multiple strengths. First, MrOS was specifically designed to study LUTS 
prospectively in elderly men.30 Second, the large sample size and excellent follow-up 
allowed us to evaluate multiple trajectory solutions and optimally characterize long-term 
LUTS changes. The small overall mean change in the AUA-SI during follow-up observed 
by us and others, 20,22–25 belies the dynamic nature of untreated LUTS among elderly men. 
Trajectory analysis revealed rare patterns that have not been described previously including 
persistently severe symptoms and mixed progression and remission. Finally, the 
comprehensive data available in MrOS allowed a comprehensive investigation of risk 
factors for LUTS change.
Conclusion
Several lifestyle and factors were associated with progressing and remitting LUTS 
trajectories. Back pain and CNS medication use may represent novel etiologies of LUTS 
that could be explored in future research. Intervening on lifestyle and health factors, 
especially mental health, has the potential to reduce the burden of LUTS in older men.
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Figure 1. 
Study flow diagram illustrating the selection of the analytic cohort of 1740 men from the 
Osteoporotic Fractures in Men (MrOS) Study, USA, 2000–2009.
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Figure 2. 
Trajectory shape as illustrated with plots of mean American Urologic Association-Symptom 
Index (AUA-SI) scores over time among elderly men never treated for lower urinary tract 
symptoms (LUTS), the Osteoporotic Fractures in Men (MrOS) Study, USA, 2000–2009.
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Figure 3. 
Percentages of men in stable, progressing or remitting trajectories according to baseline 
LUTS severity, the Osteoporotic Fractures in Men (MrOS) Study, USA, 2000–2009.
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Table 1
Baseline Characteristics among Men with no History of LUTS Treatment and the Analytic Sample Derived 
from this Initial Cohort, the Osteoporotic Fractures in Men (MrOS) Study, USA, 2000–2009.
Characteristic
Men with no History of Treatment for LUTS 1
N=3 594
Analytic Sample
N=1 740
Mean (SD) Mean (SD)
Age (years) 72.7 (5.6) 71.4 (4.8)
BMI (kg/m2) 27.3 (3.8) 27.3 (3.7)
PASE Score2 152 (69) 158 (66)
SF-12 Physical Component Score 50 .0 (9.6) 51.4 (8.1)
SF-12 Mental Component Score 55.7 (6.8) 56.3 (6.0)
AUA-SI 7.3 (5.7) 6.0 (4.8)
Percent (%) Percent (%)
Race/Ethnicity
 Caucasian 89% 90%
 African American 4% 3%
 Asian 3% 3%
 Hispanic/Other 3% 3%
High school education or less 24% 23%
Live alone 13% 11%
Cigarette Smoking
 ≥40 pack years 17% 15%
 20–39.9 pack years 17% 19%
 <20 pack years 27% 27%
 None 38% 39%
Alcohol Consumption
 ≥14 drinks/week 12% 13%
 7–13.9 drinks/week 14% 16%
 ≤6.9 drinks/week 40% 40%
 None 33% 32%
History of Problem Drinking 16% 16%
Walk Daily for Exercise 50% 51%
Mobility Limitation 11% 8%
Benign Prostatic Hyperplasia 29% 25%
Diabetes 11% 9%
Hypertension 38% 36%
Anti-hypertensive use
 Diuretic 17% 13%
 Non-diuretic 27% 25%
Statins 25% 24%
Central nervous system medication use 10% 8%
Herbal supplements for LUTS/BPH 12% 10%
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1
Men untreated at baseline and with no prostate cancer history.
2
Physical Activity Scale for the Elderly (PASE).36 Higher scores indicate greater activity. Percentages may not add to 100% due to rounding.
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Table 3
Comparison of baseline demographic, lifestyle, quality of life and medical factors among elderly men in 
remitting compared to progressing trajectories.1
AUA-SI 8–19 points (moderate)
Trajectory type Remitting Progressing
PNumber in group 82 242
Age Group 0.49
65–69 years 35% 41%
70–74 years 30% 31%
≥75 years 34% 28%
White race 91% 93% 0.56
High school education or less 29% 21% 0.15
Live alone 7% 9% 0.62
BMI≥25.0 kg/m2 68% 76% 0.15
Cigarette Smoking 0.17
 ≥40 pack years 10% 19%
 20–39.9 pack years 15% 18%
 <20 pack years 34% 27%
 None 41% 36%
Alcohol Consumption 0.67
 ≥14 drinks/week 10% 13%
 7–13.9 drinks/week 15% 18%
 ≤6.9 drinks/week 40% 36%
 None 35% 33%
History of Problem Drinking 12% 23% 0.03
Caffeine Intake 0.25
 Quartile 1 26% 20%
 Quartile 2 26% 25%
 Quartile 3 29% 25%
 Quartile 4 20% 30%
Physical Activity Score2 0.84
 0–99 points 24% 20%
 100–149 points 30% 31%
 150–199 points 27% 30%
 ≥200 points 18% 19%
Walk Daily for Exercise 56% 45% 0.28
Mobility Limitation 11% 8% 0.46
SF-12 Physical Component Score 0.31
 <50 points 43% 33%
 50–54 points 21% 26%
 ≥55 points 37% 41%
SF-12 Mental Component Score 0.43
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AUA-SI 8–19 points (moderate)
Trajectory type Remitting Progressing
PNumber in group 82 242
 <50 points 13% 19%
 50–54 points 12% 14%
 ≥55 points 74% 67%
Medical History
Diabetes 5% 9% 0.22
Hypertension 30% 43% 0.05
Angina 7% 16% 0.06
Myocardial infarction 12% 12% 0.96
Stroke 4% 5% 1.00
Cancer (other than prostate) 20% 21% 0.82
Trouble with dizziness 26% 27% 0.82
Back pain in past year 72% 74% 0.72
Prostatitis 15% 12% 0.47
Medications or Supplements
Hypoglycemic 4% 6% 0.39
Anti-hypertensive 0.06
 Diuretic 9% 17%
 Non-diuretic 21% 26%
Statin 24% 29% 0.47
Antidepressant 7% 4% 0.25
Central nervous system 17% 10% 0.10
Herbal use for LUTS/BPH 15% 20% 0.29
1Variables with p≤0.25 were considered for selection in logistic regression.
2
Physical Activity Scale for the Elderly (PASE).36 Higher scores indicate greater activity.
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Table 4
Factors independently associated with progressing or remitting LUTS trajectory according to baseline AUA-SI 
score.1
Baseline AUA-SI Score 0–7 points : Progressing vs. Stable
Factor Referent level OR (95% CI) p
SF-12 Mental Component Score
 <50 points2 ≥55 points 1.9 (1.1 – 3.4) 0.03
 50–54 points ≥55 points 1.5 (0.8 – 2.8) 0.21
History of cancer (not prostate) No cancer 1.7 (1.0 – 2.9) 0.03
Mobility limitation No mobility limitation 2.0 (1.0 – 3.8) 0.04
Overweight or obese (BMI ≥25.0 kg/m2) Normal/Underweight (BMI<25.0 kg/m2) 1.7 (1.0–2.8) 0.06
Trouble with dizziness No dizziness 1.6 (0.9 – 2.6) 0.08
No daily walking for exercise Daily walking for exercise 1.4 (0.9 – 2.2) 0.10
Baseline AUA-SI Score 8–19 points: Progressing vs. Stable
Factor Referent level OR (95% CI) p
SF-12 Mental Component Score
 <50 points ≥55 points 2.5 (1.3 – 4.9) 0.005
 50–54 points ≥55 points 1.5 (0.8 – 2.8) 0.22
History of diagnosed hypertension No hypertension 1.5 (1.0 – 2.4) 0.06
Back pain in past 12 mo No back pain 1.5 (1.0 – 2.4) 0.07
Live with spouse, family, or roommate Live alone 1.8 (1.0 – 3.4) 0.07
White (Caucasian) Non-white 1.9 (0.9 – 3.9) 0.10
History of diabetes No diabetes 0.6 (0.3 – 1.2) 0.12
Baseline AUA-SI Score 8–19 points: Remitting vs. Progressing
Factor Referent level OR (95% CI) p
Central nervous system medication No use 2.3 (1.1 – 4.9) 0.03
History of problem drinking No such history 0.4 (0.2 – 0.9) 0.03
History of diagnosed hypertension No hypertension history 0.6 (0.3 – 1.0) 0.04
History of diagnosed angina No angina history 0.4 (0.2 – 1.1) 0.07
High school education or less Some college or more 1.7 (0.9 – 3.1) 0.08
1
Factors evaluated during model building were those from univariable analyses with p≤0.25 and retained in the stepwise selection procedure at 
p≤0.15 as described in Methods.
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